...
机译:曲妥珠单抗和乳腺癌:发展和现状
Department of Surgery and Science Graduate School of Medical Science Kyushu University;
Department of Surgery and Science Graduate School of Medical Science Kyushu University;
Department of Surgery and Science Graduate School of Medical Science Kyushu University;
Department of Surgery and Science Graduate School of Medical Science Kyushu University;
Department of Surgery and Science Graduate School of Medical Science Kyushu University;
Department of Surgery and Science Graduate School of Medical Science Kyushu University;
Department of Surgery and Science Graduate School of Medical Science Kyushu University;
Department of Surgery and Science Graduate School of Medical Science Kyushu University;
Trastuzumab; HER2; Breast cancer; Molecular-targeted therapy;
机译:曲妥珠单抗和乳腺癌:发展和现状。
机译:接受曲妥珠单抗治疗的晚期乳腺癌患者的HER-2 / neu状态和相应的转移部位。
机译:HER2基因状态与曲妥珠单抗耐药相关的潜在潜在生物学特征的关系及其对接受曲妥珠单抗辅助治疗的乳腺癌患者生存的影响
机译:HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关:回顾性和多中心研究
机译:宠物成像探针的发展,以预测乳腺癌对曲妥珠单抗的响应(T-DM1)
机译:HER2基因状态与曲妥珠单抗耐药相关的潜在潜在生物学特征的关系及其对接受曲妥珠单抗辅助治疗的乳腺癌患者生存的影响
机译:Trastuzumab(Herceptin ® sup>)融资和报销的现状,德国乳腺癌的佐剂和晚期治疗
机译:克服HER2扩增乳腺癌对曲妥珠单抗的耐药性